



Press Release
October 20, 2021
Gothenburg, Sweden

Report from Extraordinary General Meeting of Vitrolife AB (publ)

At Vitrolife's Extraordinary General Meeting today, the following, amongst other things, was decided:

- Non-cash consideration issue in accordance with the board's proposal with the purpose of financing the acquisition of Igenomix.
- Vesa Koskinen, partner at EQT, is elected new board member and the board is thus expanded with one member. The board remuneration is increased because of the additional member. The decision is conditional on the non-cash issue being carried out.

Gothenburg, October 20, 2021
VITROLIFE AB (publ)
The Board

Contact persons:

Thomas Axelsson, CEO, tel: +46 31 721 80 01
Mikael Engblom, CFO, tel: +46 31 721 80 14

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in approximately 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Website: www.vitrolife.com

The information was submitted for publication, through the agency of the contact persons set out above, at 4.00 pm CET on October 20, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.